X4 Pharmaceuticals, Inc. (XFOR) AI Stock Analysis

X4 Pharmaceuticals, Inc. is a late-stage clinical biopharmaceutical firm focused on developing therapies for rare diseases. Its primary asset is mavorixafor, a small molecule inhibitor of the CXCR4 chemokine receptor currently in Phase III clinical trials for warts, hypogammaglobulinemia, infections, and myelokathexis syndrome, as well as Phase Ib trials for chronic neutropenia and Waldenstrom macroglobulinemia. Its pipeline also includes CXCR4 antagonists X4P-002 for brain cancers and X4P-003 for primary immunodeficiencies. X4 Pharmaceuticals partners with Abbisko Therapeutics Co., Ltd. to develop and commercialize mavorixafor in combination with checkpoint inhibitors for oncology indications.

Annual revenue rose from $3.5M in FY2018 to $35.1M in FY2025, representing a 4-year revenue CAGR of 78.0%. In FY2025, revenue grew 1273.2% while gross margin reached 82.2%, up from 68.8% in FY2024. However, operating margin remained negative at -247.4% in FY2025, resulting in net income of -$79.2M and an EPS of -$4.34. Over the trailing twelve months ending June 30, 2026, revenue stood at $15.8M with an operating margin of -186.1% and EPS of $0.02, supported by quarterly revenue growth of 346.3% year-over-year.

As of June 30, 2026, X4 Pharmaceuticals reported cash and short-term investments of $208.0M and total debt of $77.2M, providing net cash of $130.7M. Total assets were $253.1M against shareholders' equity of $155.5M. The company maintains liquidity with a current ratio of 11.30 and a debt-to-equity ratio of 0.50. In FY2025, operating cash flow was -$85.6M and free cash flow was -$88.6M, with capital expenditures of $3.0M. Share count increased by 12965.6% over five years.

XFOR closed at $2.59 on October 16, 2026, with a market cap of $256.8M and enterprise value of $177.6M. The stock trades at a trailing P/E of 129.5x, compared to the 24.6x median of its US-listed Healthcare peers. Its price-to-sales ratio is 16.2x relative to the peer median of 4.1x, while its EV/EBITDA stands at 1.1x versus the peer median of 12.0x. Over the past year, XFOR fell 12.8% and is down 35.2% year-to-date, trailing the S&P 500 (SPY) 1-year gain of 16.8%.

Wall Street coverage includes 5 Strong Buy ratings, 0 Buy, 0 Hold, and 0 Sell ratings. The mean price target of $11.60 sits 347.9% above the last close of $2.59. For the fiscal year ending December 31, 2026, consensus estimates project an EPS of -$0.67 on revenue of $16.0M. For the following fiscal year, 4 analysts anticipate revenue will decline 27.7% to $11.6M. The company beat EPS estimates in all 4 of the last 4 quarters, and its next earnings date is November 4, 2026.

This page is an AI-written research summary of X4 Pharmaceuticals, Inc. (XFOR). The text was generated on October 30, 2026 from Quotelinks data as of October 16, 2026 (company profile, annual results, latest balance sheet, valuation, price performance and analyst estimates). An automatic check rejects any draft that contains a figure not found in that data. It is not investment advice; verify figures on the linked tabs before making decisions.

Related: XFOR income statement, XFOR balance sheet, XFOR key metrics, XFOR analyst forecast, XFOR chart. See the XFOR stock overview for the latest quote and news.